MedPath

Infranodal Conduction Time During TAVR as Predictor of HAVB

Not Applicable
Conditions
High-degree AV Block
Severe Aortic Valve Stenosis
Left Bundle-Branch Block
Registration Number
NCT04128384
Lead Sponsor
University Hospital, Saarland
Brief Summary

Consecutive patients with high grade aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) with a self-expanding valve (Medtronic CoreValve Evolut R® or Edwards Sapien S3®) without pre-existing pacemaker devices are eligible for inclusion. During the TAVR procedure, an electrophysiologic study including measurements of infranodal conduction times (HV-interval before and after valve implantation) will be performed. Electrocardiograms before TAVR, before discharge, after 30 days and after 12 months will be analyzed regarding new onset LBB and the occurrence of high-degree AV block (HAVB) .

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200
Inclusion Criteria
  1. Indication for TAVR according to current guidelines
  2. Written informed consent
Exclusion Criteria
  1. Pre-existent intracardiac device as pacemaker, implanted cardioverter defibrillator or CRT-P/CRT-D device

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
High-degree AV block24 months

Occurence of high-degree AV block necessitating a pacemaker implantation during follow up

Persistence of left bundle-branch block24 months

Persistence of new onset left bundle branch-block following TAVR procedure

Secondary Outcome Measures
NameTimeMethod
Differences between implanted valve types on ifranodal conduction24 months

Trial Locations

Locations (1)

Universitätsklinikum des Saarlandes

🇩🇪

Homburg, Saarland, Germany

Universitätsklinikum des Saarlandes
🇩🇪Homburg, Saarland, Germany
Christian Ukena, MD
Contact
004968411615912
christian.ukena@uks.eu
Valerie Pavlicek, MD
Contact
004968411615912
valerie.pavlicek@uks.eu

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.